Quarterly ResultAug 13, 2026, 04:45 PM
BioXcel Therapeutics Faces Substantial Doubt on Going Concern
AI Summary
BioXcel Therapeutics reported substantial doubt about its ability to continue as a going concern, citing significant losses, negative cash flows, and current debt obligations. The company is actively pursuing strategic transactions or additional financing, warning of potential bankruptcy if unsuccessful. For Q2 2026, the company reported a net loss of $14.7 million on product revenue of $0.18 million, with an accumulated deficit reaching $747.5 million.
Key Highlights
- BioXcel Therapeutics faces substantial doubt about its ability to continue as a going concern.
- Net loss for Q2 2026 was $14.7 million, compared to $19.2 million for Q2 2025.
- Product revenue increased to $0.18 million in Q2 2026 from $0.12 million in Q2 2025.
- Accumulated deficit reached $747.5 million as of June 30, 2026.
- Cash and cash equivalents decreased to $12.8 million from $28.4 million since December 31, 2025.
- Current portion of long-term debt increased to $104.5 million as of June 30, 2026.
- Net cash used in operating activities was $17.9 million for the first six months of 2026.
- Company is engaged in contingency planning, including potential debtor-in-possession financing.
Price Impact
More from BTAI